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The widespread use of imaging examinations has increased the detection of incidental adrenal lesions, which are
mostly benign and non-functioning adenomas. The differentiation of a benign from a malignant adrenal mass can
be crucial especially in oncology patients since it would greatly affect treatment and prognosis. In this setting,
imaging plays a key role in the detection and characterization of adrenal lesions, with several imaging tools which
can be employed by radiologists. A thorough knowledge of the imaging features of adrenal masses is essential to
better characterize these lesions, avoiding a misinterpretation of imaging findings, which frequently overlap
between benign and malignant conditions, thus helping clinicians and surgeons in the management of patients.
The purpose of this paper is to provide an overview of the main imaging features of adrenal masses and tumor-like
conditions recalling the strengths and weaknesses of imaging modalities commonly used in adrenal imaging.
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 Adenoma is the most common adrenal tumor
 Washout evaluation of adrenal masses on CECT is
the gold standard technique
 Chemical shift MR imaging is a useful tool to
identify intra-lesional fat content
 DWI is not useful to differentiate adrenal lesions
 Nuclear medicine techniques are helpful in some
specific settingsIntroduction
The adrenal gland is a site of several pathologic condi-
tions, including hyperplasia, hemorrhage, and malignant
and benign masses. Tumors can be hyperfunctioning,
when producing an increased amount of hormones lead-
ing to endocrine disorders, or non-hyperfunctioning,
which are characterized by normal hormone levels.
Therefore, in some cases, these lesions can be clinically
suspected, but in most cases adrenal masses are discov-
ered incidentally. Indeed, the increasing use of imaging
investigations, including ultrasound (US), computed* Correspondence: albanodomenico@me.com
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the Creative Commons license, and indicate iftomography (CT), and magnetic resonance (MR), has led
to an increase in the detection of such incidental lesions
[1–4]. Incidental adrenal masses are common, occurring in
about 3–7% of adults [3], with the majority of them being
benign non-functioning adenomas [4]. Characterization of
an adrenal mass as benign or malignant is critical and im-
aging plays a key role in influencing the clinical manage-
ment of patients. In this setting, the role of radiologists is
crucial in both the choice of imaging modality and proto-
col technique to be used and interpretation of imaging
findings. US has a limited part in the assessment of adre-
nals due to its low accuracy in the detection and
characterization of small adrenal neoplasms, in comparison
to CT and MR, being useful to differentiate a cystic from a
solid mass. Nevertheless, US has still a major role in neo-
natal patients in which the adrenals are bigger compared
to the kidneys. CT represents the first-level imaging mo-
dality for the evaluation of adrenal lesions, since it permits
a quick execution ensuring high spatial resolution, with
findings of pre-contrast images and post-contrast behavior
being commonly used to achieve a correct diagnosis [5].
MR still remains a second-level technique, although its ad-
vantages include multiparametricity, multiplanarity, higher
contrast resolution in comparison with CT, and the added
value of chemical shift imaging (CSI) [6].is distributed under the terms of the Creative Commons Attribution 4.0
rg/licenses/by/4.0/), which permits unrestricted use, distribution, and
e appropriate credit to the original author(s) and the source, provide a link to
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renal imaging. When the clinical laboratory picture
shows a suspicious functioning adrenal lesion, nuclear
medicine techniques such as scintigraphy with 131/
123I-meta-iodo-benzyl-guanidine (MIBG) and Octreotide
can be used. Moreover, positron emission tomography
(PET) has also shown to be helpful for the evaluation of
non-hyperfunctioning adrenal masses with high accuracy
in the characterization of malignant lesions [7].
The purpose of this paper is to give an overview of the
imaging features of adrenal masses and tumor-like con-
ditions with an emphasis on CT and MR. We will also
briefly discuss the recent advancements in diagnostic
radiology and nuclear medicine modalities.Anatomy
The adrenals are paired retroperitoneal glands that lie
superiorly and anteromedially to the kidneys. They are
triangular-shaped with the right adrenal gland being
usually more pyramidal in shape [8]. The adrenal glands
are made of an outer cortex deriving from the meso-
derm and an inner medulla deriving from the neural
crest. In the cortex, the zona glomerulosa produces min-
eralocorticoids, the zona fasciculata glucocorticoids, and
the zona reticularis sex steroids or gonadocorticoids,
whereas the medulla produces catecholamines, adren-
aline, and noradrenaline. The adrenals are supplied by
three arteries: superior (from the inferior phrenic arter-
ies), middle (from the abdominal aorta), and inferior
suprarenal arteries (from the renal arteries). The right
adrenal vein ends into the inferior vena cava, while the
left adrenal vein ends into the left renal vein or inferior
phrenic vein. The lymphatic vessels drain to the
para-aortic nodes. The innervation of adrenals comes
from the splanchnic nerves arising from the aortic and
renal plexuses [9].Benign adrenal tumors and tumor-like conditions
Cortical adenoma
Adenoma is the most common benign adrenal tumor, with
no malignant evolution, arising from the cortex and con-
sisting of clear cells with abundant intracytoplasmatic fat,
which is the key element for the differential diagnosis with
malignant neoplasms at imaging. Typically, the remaining
portion of the adrenal gland and the contralateral adrenal
appear atrophic. Large adenomas may show cystic compo-
nents, calcifications, and hemorrhagic areas [10].
Incidence of adenomas increases with age and most of
them are non-functioning, with these lesions being gener-
ally asymptomatic and incidentally discovered [11]. Hyper-
functioning adrenal adenomas present with symptoms and
signs related to excess hormone secretion, thereby deter-
mining Cushing’s syndrome (hyperproduction of cortisol)or Conn’s syndrome (hyperproduction of aldosterone),
while they rarely lead to an adrenal-genital syndrome [12].
The typical adenoma measures less than 3 cm making
challenging its detection through US, in which it appears
as a homogeneous and hypoechoic solid lesion with
well-defined margins, hypovascularization on Color Dop-
pler examination [13], and hypoenhancing on contrast-
enhanced US (CEUS) [14]. At unenhanced CT, adenomas
are usually well-demarcated round or oval lesions, with
homogeneous and relatively low attenuation values (lower
than 10 Hounsfield Units [HU]), due to high fat content
[15]. However, unenhanced CT alone is not always diag-
nostic since 15–30% of adenomas are lipid-poor, thereby
showing higher attenuation values. In these cases, add-
itional imaging after intravenous contrast administration is
required to differentiate adenoma from non-adenomas.
The evaluation of the enhancement pattern of adrenal le-
sions needs a further late phase after the acquisition of the
venous phase. There are different CT protocols suggested
for the evaluation of adrenal masses; however, there is evi-
dence that a 15-min post-contrast protocol has the highest
diagnostic accuracy [16–20].
Absolute percentage washout (APW) is calculated
using the following formula:
enhanced HU−15-min delayed HUð Þ
= enhanced HU−unenhanced HUð Þ  100%
Relative percentage washout (RPW) is used when
unenhanced CT value is not available, and the enhanced
values are compared with 15-min delayed scans, by
using the following formula:
enhanced HU−15-min delayed HUð Þ= enhanced HUð Þ  100%
If the APW is > 60% or RPW is > 40% after 15-min
from contrast administration, this is indicative of aden-
oma, with sensitivity and specificity of 88% and 96% at
the APW and sensitivity and specificity of 83% and 93%
at the RPW, respectively [5]. This method enables to dif-
ferentiate adenomas, which enhance quickly and show
rapid washout, from non-adenomas such as metastases,
which instead demonstrate strong enhancement but pro-
longed washout. Another useful imaging feature is the
size, since lesions greater than 4 cm lay for malignant tu-
mors, and the dimensional growth, considering that ad-
enomas grow slower than malignant masses [21].
MR has similar diagnostic accuracy to CT allowing char-
acterizing adenomas regardless of their CT enhancement
(Fig. 1) [6]. On T2-weighted MR images, adrenal aden-
omas are homogeneous and present intermediate-low sig-
nal intensity compared to skeletal muscle or liver;
intra-lesional hemorrhage can occur in large adenomas
resulting in hyperintense areas on T1-weighted images
[20]. An important component of adrenal MR protocol is
Fig. 1 Adrenal adenoma of a 45-year-old woman. Unenhanced CT
(a) shows a left adrenal mass (arrow) with lower attenuation values
than 10 HU. Axial T1-weighted in-phase (b) and out-of-phase (c)
gradient recalled echo MR images show prominent loss of signal
on out-of-phase
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cies of protons in both water and fat within the same
voxel and creates in-phase and opposed-phase images,
which enable to detect intra-lesional fat resulting in a loss
of signal intensity in the opposed phased images [6]. Thus,most adrenal adenomas demonstrate a loss of signal inten-
sity on out-of-phase images, and a decrease in signal in-
tensity of more than 20% is considered diagnostic of
adenoma. The MR sensitivity for adenomas measuring
10–20 HU is nearly 100%, while that for lipid-poor
adenomas measuring greater than 30 HU is significantly
lower (13–75%) [10, 22]. The loss of signal intensity can
be also quantified using parameters such as the
spleno-adrenal ratio (ASR) and the signal intensity index
(SII). An ASR < 70% is highly specific for adenoma and
has sensitivity of 78%; while using SII, a loss of signal in-
tensity greater than 5% has allowed to identify adenomas
in 100% of cases [23]. Of note, Namimoto et al. reported
similar results in the identification of adenomas by com-
paring three-point Dixon techniques for CSI and conven-
tional dual-echo imaging [24].
In comparison to contrast-enhanced CT (CECT),
contrast-enhanced MRI with gadolinium washout stud-
ies does not appear to exhibit the same diagnostic
strength. Thus, CECT remains the gold standard tech-
nique, especially in the evaluation of lipid-poor aden-
omas. Data related to diffusion-weighted imaging (DWI)
of adrenal masses have been disappointing mainly due
to benign adrenal adenomas’ propensity to demonstrate
restricted pattern of diffusion. Miller et al. retrospect-
ively evaluated 160 adrenal lesions and found that appar-
ent diffusion coefficient (ADC) was not useful to
differentiate benign from malignant adrenal neoplasms
[25]. Sandrasegaran et al. also found that ADC values
were not helpful for this purpose [26].
Over the last years, CT perfusion imaging has been
widely used for the diagnosis and characterization of tu-
mors, but few studies about its potential role in the
characterization of adrenal lesions have been reported.
Perfusion imaging evaluates tissue vascularity after con-
trast media administration by measuring changes in tissue
enhancement and perfusion. Previous studies have showed
that a perfusion parameter indicated as blood volume is
significantly higher in adenomas, being potentially helpful
to differentiate adenomas from non-adenomas [27].
Regarding the role of dual energy CT, studies have re-
ported that this imaging modality allows an accurate
characterization of lipid-rich adenoma evaluating that a
decrease in attenuation of an adrenal lesion between 140
and 80 kVp is a highly specific sign of adenoma. How-
ever, because an increase in attenuation at 80 kVp is
seen on metastatic lesions and some adenomas, the sen-
sitivity of this modality is still low [28].
Few data have been published on nodule
characterization by histogram analysis, thus there is poor
knowledge regarding the potential application of this
tool. This method also takes advantage of the higher
intracytoplasmatic fat content of adenomas. With a
threshold value of > 10% negative pixels, it is possible to
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values > 10 HU on unenhanced CT with high accuracy;
moreover, a threshold of > 10% negative pixels seems to
guarantee 100% specificity [29]. New interesting perspec-
tives include the characterization of adrenal lesions by
using texture analysis, with some reports already show-
ing promising results by some texture analysis-derived
features [30].Hyperplasia
Hyperplasia refers to nonmalignant diffuse or focal en-
largement of the adrenal gland, which is an uncommon
cause of ACTH-independent Cushing’s syndrome or
Conn’s syndrome. Adrenal hyperplasia can be congenital
or acquired and is classified according to morphology in
diffuse or nodular adrenal hyperplasia [31]. Among the
causes of ACTH-independent Cushing’s syndrome, we
should recall primary pigmented nodular adrenal disease
(PPNAD), which is a benign condition generally charac-
terized by mild symptoms related to hypercortisolism. In
patients with PPNAD, imaging allows to identify mul-
tiple small nodules in normal-sized or enlarged adrenal
glands [32].Fig. 2 Bilateral adrenal hyperplasia in a 75-year-old woman. Axial T1-weigh
weighted fast spin echo (c), and three dimensional fat-suppressed T1-weig
injection (d) show the nodular enlargement of both adrenal glands (arrowsAt CT, diffuse hyperplasia is characterized by the in-
creased volume of both adrenals presenting smooth
margins, a homogeneous structure, and often some nod-
ules of variable size, usually smaller than 5–10 mm, but
even up to 2 cm. A large nodule is rarely detected and it
differs from the adenoma because the former lies within
enlarged glands, while the latter appears within an atro-
phic adrenal gland or associated with atrophy of the
contralateral gland [33]. Hyperplasia contains variably
sized groups of lipid-rich cells, thereby showing a signifi-
cant overlap with adenoma in terms of lesion attenu-
ation and APW or RPW [33]. On MR, hyperplasia
shows signal intensity similar to that of the normal gland
but appears as homogeneous or nodular enlarged gland;
this appearance helps in the differentiation from other
nodular pathologies, which are generally hyperintense
on T2-weighted images (Fig. 2) [34].
Adrenal infection
Tuberculosis is one the most frequent adrenal infections,
still being the primary cause of primary adrenal insuffi-
ciency in developing countries. Generally, tuberculosis
affects both adrenal glands and the clinical picture is
that of adrenal insufficiency, including weakness, nausea,ted in-phase (a) and out-of-phase gradient recalled echo (c), T2-
hted gradient recalled echo image in portal phase after contrast
) with loss of signal on out-of-phase (b)
Fig. 3 Right adrenal hemorrhage in a 61-year-old man with acute
abdominal pain after starting anticoagulant therapy. Axial
unenhanced (a) and arterial (b) phase CT images show a large right
adrenal hematoma (arrow) with relatively high attenuation values
and without enhancement after contrast injection
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Depending on the disease stage, CT and MR show differ-
ent findings. At first, a mass-like enlargement with pre-
served contour is commonly detected. Central low
attenuation on unenhanced CT and peripheral enhance-
ment on post-contrast CT and MR images is another
typical imaging finding due to a central caseous necrosis
area [35]. Later, a decrease in size of adrenal glands is
observed with the frequent occurrence of diffuse, local-
ized, or punctuated calcifications, with atrophic adrenal
glands with calcifications being considered highly suspi-
cious for chronic tuberculosis [36]. During antitubercu-
losis therapy, the caseous necrosis can be replaced by
fibrous tissue and cicatrix, thereby leading to a more
homogeneous enhancement or central calcific deposits
[36]. Another adrenal infection mimicking tuberculosis
is histoplasmosis, although neoplastic conditions such as
metastases or lymphoma may show similar imaging fea-
tures. Thus, histologic evaluation of adrenal tissue after
biopsy is generally required to achieve the correct
diagnosis.
Adrenal hemorrhage
Adrenal hemorrhage is a condition with different etio-
pathogenetic, clinical, and prognostic aspects depending
on whether it occurs in children or in adults. Adrenal
hemorrhage can result from trauma, anticoagulant ther-
apy, complicated pregnancy, sepsis, or stress, such as
surgery [37, 38]. Moreover, adrenal hemorrhage may
occur within adrenal lesions such as adenoma, myeloli-
poma, pheochromocytoma, metastasis, and cortical car-
cinoma. Trauma is the most common cause, with
post-traumatic hemorrhage being usually unilateral [37].
Bilateral hemorrhage occurs in 20% of cases, and adrenal
insufficiency secondary to hemorrhage is extremely rare
[38]. US represents the first-level imaging modality in
children. Acute hemorrhage appears as a mass with a
diameter of 3–4 cm with a mixed echostructure, pre-
dominantly hyperechogenic due to blood clots within
the hematoma. In the subsequent phases, the mass pro-
gressively becomes liquid and then hypo-anechoic due
to the lysis of the clots. At Color Doppler, adrenal
hemorrhage shows no vascularization [38].
On CT, acute hemorrhage is characterized by high at-
tenuation values, in post-traumatic cases, associated with
hemorrhagic suffusion of periadrenal fat and retroperi-
toneal bleeding (Fig. 3). A chronic hematoma appears as
a mass with a hypoattenuating center with or without
calcifications, also termed adrenal pseudocyst. Hemato-
mas usually decrease in size and may spontaneously dis-
appear. Calcifications may develop in the late stage of
hemorrhages [38].
On MR, signal intensity of adrenal hemorrhage depends
on its stage. In the acute stage (first 7 days), the hematomaappears isointense or slightly hypointense on T1-weighted
and hypointense on T2-weighted images, due to the pres-
ence of deoxyhemoglobin. In the subacute phase (1 week
to 7 weeks), the hemorrhage appears hyperintense on both
T1- and T2-weighted images due to the paramagnetic ef-
fect of the methemoglobin. In the chronic stage (more
than 7 weeks), a hypointense rim on T1- and T2-weighted
images due to hemosiderin deposition and fibrosis is de-
tectable [38].
Cyst
Adrenal cysts are uncommon. Traditionally, adrenal
cysts have been classified as pseudocysts (resulting from
previous hemorrhage), endothelial cysts (with a thin
endothelial wall and lactescent liquid, deriving from lym-
phangiectasia or arteriovenous malformations), epithelial
cysts (with thin epithelial wall and serous liquid con-
tent), and parasitic cysts (hydatid disease). These cysts
can range in size from 1 to 20 cm [39, 40]. At US,
Fig. 4 Right adrenal cyst in a 50-year-old woman. Axial T2-weighted
fat-saturated fast spin echo MR image (a), three-dimensional fat-
suppressed T1-weighted gradient recalled echo images before (b)
and after paramagnetic contrast administration (c) show a right
adrenal cystic lesion (arrow) with low T1 signal intensity, high T2
signal intensity, no contrast enhancement and no septations, blood
products, soft-tissue components, or calcifications
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well-circumscribed hypoechoic or anechoic lesions with
thin walls, while pseudocysts may have thicker walls.
The scattered echogenicity, the presence of debris, or
fluid-fluid levels suggest previous hemorrhage into a
pseudocyst [40]. On CT, adrenal cysts appear as
well-demarcated, non-enhancing, hypoattenuating lesion
with water attenuation (< 20 HU) and thin walls. Never-
theless, pseudocysts may have a minimally thick cyst
wall and complicated fluid [31]. In some cases, internal
hemorrhage or calcifications can be detected, especially
in pseudocysts and parasitic cysts. On MR, cysts are
usually hyperintense on T2-weighted images (Fig. 4).
Septations, blood products, or a soft-tissue component
and calcifications may be observed in pseudocysts [31].
Myelolipoma
Adrenal lipomatous tumors are neoplasms with a signifi-
cant proportion of adipose tissue, with myelolipoma be-
ing the most common type. Myelolipoma is a benign
tumor, usually unilateral, small, and often incidentally
discovered. It consists of mature fat and hematopoietic
cells from myeloid, erythroid, and megakaryocytic lines.
The amount of fatty component is variable with some
tumors showing small regions of fat within a predomin-
antly soft-tissue mass, whereas others consist almost
completely of fat. It can infrequently contain calcifica-
tions or show partial replacement by hemorrhage or fi-
brosis. Large lesions tend to become symptomatic due
to pressure effects and to intra-lesional hemorrhage or
infarctions. While smaller lesions can be managed con-
servatively, those with a size of more than 4 cm are likely
to be surgically removed. Indeed, the American Associ-
ation of Clinical Endocrinologists and American Associ-
ation of Endocrine Surgery (AACE/AAES) 2009
guidelines recommend adrenalectomy for all myelolipo-
mas measuring more than 4 cm [41].
At US, fat-predominant lesions appear hyperechoic,
while myelolipomas mainly composed of myeloid ele-
ments appear hypoechoic. Frequently, the lesion has
mixed hyperechoic and hypoechoic areas, due to varying
amounts of fat and myeloid elements [42].
At CT, myelolipoma appears as a round mass with
well-defined borders. The density varies depending on
the proportion of fat and myeloid components. Internal
inhomogeneity is related to intra-lesional septa, necrosis,
hemorrhage, or calcifications. Thus, myelolipoma goes
from totally fat lesions with thin circles of parenchymat-
ous tissue to clearly parenchymatous forms with small
areas of fat. At CT, myelolipoma is easily diagnosed be-
cause gross fat, with attenuation values < − 30 HU, is al-
most always detectable. After contrast agent injection,
myelolipoma typically shows slight enhancement be-
cause it is poorly vascularized [31, 42].On MR, the fat macroscopic components are hyperin-
tense on T1- and T2-weighted images, while the
hematopoietic parts are hypointense on T1- and moder-
ately hyperintense on T2-weighted images. The diagno-
sis becomes certain when the hyperintensity on
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suppression [41, 42]. Similar to renal angiomyolipomas,
the presence of the India ink artifact on CSI at the
myelolipoma-adrenal interface or within an adrenal mass
on opposed-phase images should indicate a myelolipoma
[43]. Fat-suppressed images show greater loss of signal
intensity than CSI sequences, as the presence of macro-
scopic adipose tissue is typical of myelolipoma (Fig. 5).
On contrast-enhanced MR, myelolipoma may have en-
hancement of the myeloid component. Based on MR
characteristics, three different types of myelolipoma
were described. The first is mostly composed of fat and
homogeneous and hyperintense on T1-weighted images.
The second consisted of similar content of fat and mye-
loid components with a heterogeneous appearance. The
third type is mainly composed of myeloid tissue with en-
hancement after contrast injection [9].Fig. 5 Left adrenal myelolipoma incidentally discovered in a lumbar CT sca
with macroscopic fat (arrowhead) and a soft-tissue myeloid component (ar
spin echo (c), T1-weighted in-phase (d), and out-of-phase gradient recalled
suppressed T2-weigthed images (c, arrowhead) and show loss of signal onLipoma
Adrenal lipomas are rare tumors of mesenchymal origin
containing mature fatty tissue and surrounded by a fi-
brous capsule, similarly to lipomas elsewhere in the
body, with only a few cases having been reported in the
adrenals [44, 45]. These are well-demarcated lesions
composed of lobules of fat tissue. On CT, in contrast to
myelolipomas, they show no or minimal soft-tissue at-
tenuation and can contain focal areas of intra-lesional
calcifications due to degenerative changes [44, 45].
Pheochromocytoma
Pheochromocytoma arises from the chromaffin cells of
the adrenal medulla and typically produces both nor-
epinephrine and epinephrine [46]. Extra-adrenal pheo-
chromocytomas are uncommon and are termed
paragangliomas, originating in the sympathetic ganglian on a 51-year-old man. Unenhanced CT (a) shows a left adrenal mass
row). Axial T2-weighted fast spin echo (b), T2-weighted fat-saturated
echo images (e) show the signal drop of macroscopic fat in fat-
out-of-phase imaging of the myeloid element (e, arrow)
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Adrenal pheochromocytoma is commonly benign, al-
though 10% of these lesions can be malignant [46]. Ma-
lignant pheochromocytomas are recognized for local
infiltration or metastases, usually involving the bone,
liver, lymph nodes, lungs, and brain. Clinical symptoms
are associated with catecholamine excess (headache,
sweating, palpitations, pallor, weight loss, and/or anx-
iety). This tumor is generally sporadic, although it can
be associated with hereditary syndromes including mul-
tiple endocrine neoplasia (MEN)-2A, MEN-2B, von
Hippel-Lindau, and NF-1. Pheochromocytomas are vari-
able in size ranging from 1.2 to 15 cm with a mean size
of 5.5 cm [13, 31]. When a pheochromocytoma is sus-
pected, the first diagnostic step is the evaluation of cate-
cholamines and metanephrines in urine.
The diagnosis of pheochromocytoma at imaging is
often challenging due to its complex and variable ap-
pearance, related to necrosis, fibrosis, cystic and fatty de-
generation, and calcification, which has led to describe it
as “imaging chameleons” mimicking other lesions [47].
At US, pheochromocytomas are heterogeneous and
well-encapsulated, with hypervascularization at color
Doppler and an early arterial pattern of enhancement at
CEUS [48, 49].
At CT, pheochromocytomas may present solid, cystic,
calcific, and/or necrotic components. Smaller tumors
tend to display a more uniform attenuation, with a dens-
ity of 40–50 UH [47, 49]. After contrast administration,
pheochromocytomas enhance avidly with some of them
showing higher enhancement on the portal venous phase
and other on the arterial phase; nevertheless, their APW
and RPW are similar to those of adenomas [49]. There-
fore, pheochromocytomas often cannot be reliably differ-
entiated from adenomas using CT washout protocols.
When lesions are quite large (> 6 cm), intra-lesional
hemorrhage, necrosis, or calcifications can be observed,
determining the inhomogenous contrast enhancement.
MR is highly sensitive for the diagnosis of pheochro-
mocytomas with a sensitivity of about 98% [49]. Pheo-
chromocytoma is slightly hypointense on T1-weighted
and hyperintense on T2-weighted images [50]. It does
not present loss of signal intensity on opposed-phase im-
ages, unlike the typical adenoma (Fig. 6). In some cases,
areas of fatty degeneration can be encountered, leading
to slight signal drop on CSI [6]. Although DWI has not
a key role in the differentiation of benign and malignant
adrenal lesions [25, 26], it is potentially useful to detect
pathologic lymph nodes and liver metastases. Neverthe-
less, a study performed at 3 T has reported significantly
lower ADC values of malignant pheochromocytomas in
comparison to benign ones [51]. MR spectroscopy has
also been used to characterize adrenal masses and par-
ticularly pheochromocytomas, postulating that metaboliccontent can be measured using that modality. Specific-
ally, it was found that pheochromocytomas exhibit a
unique spectral appearance, with the most prominent
resonating peak at 6.8 ppm, with other resonance peaks
at 2.7, 3.16, and 3.8 ppm, attributable to catecholamines
and catecholamine-derived metabolites. However, the
use of this technique has been remarkably limited by the
anatomical location of the adrenal glands, as their vicin-
ity to the diaphragm makes the analysis quite demanding
[52]. 131/123I-MIBG scintigraphy is currently the func-
tional nuclear medicine imaging of choice for pheochro-
mocytoma [11] but suffers from drawbacks like limited
spatial resolution, difficulty in detection of small tumors
(< 1.5–2.0 cm) or large tumors with extensive necrosis/
hemorrhage, lack of tracer uptake in some tumors, and
interference with certain medications, leading to
false-negative results [53]. Expression of somatostatin re-
ceptors by pheochromocytoma facilitates targeted PET
imaging with 68Ga-DOTA-peptides. In a study of
Sharma et al., 68Ga-DOTANOC PET/CT showed high
diagnostic accuracy (on patient-based analysis sensitivity,
specificity, and accuracy of 92%, 85%, and 90%, respect-
ively) in patients with a suspicion of pheochromocy-
toma, and was superior to MIBG imaging [54].
Furthermore, the properties of uptake and storage of
catecholamines in pheochromocytomas open the poten-
tial use of 18F-FDOPA PET/CT for the evaluation of the
relationship between tumor secretion and its biochem-
ical phenotype [55].Hemangioma
Hemangioma is an uncommon incidental adrenal le-
sion generally discovered by CT or MR, especially in
women between 40 and 70 years of age. Regarding the
histologic types, the most common are capillary and
cavernous hemangiomas [56]. Its radiologic features
are similar to those of hepatic and soft-tissue hem-
angiomas. On US, hemangioma has no specific char-
acteristics, appearing as a mass with variable size and
echotexture. On CT, small hemangiomas can be
homogeneous, whereas larger lesions present calcifica-
tions which can be either phleboliths or dystrophic
calcifications due to previous hemorrhages [31]. On
CECT, hemangioma shows heterogeneous and mainly
peripheral enhancement, with or without central fill-
ing on delayed phases (Fig. 7) [31]. At MR,
hemangioma is hypointense on T1-weighted with a
remarkable hyperintensity on T2-weighted images
(lightbulb sign). Hypointense foci can be encountered
on T1- and T2-weighted images related to intra-
lesional calcifications. Also on contrast-enhanced MR,
hemangioma usually displays peripheral nodular
enhancement.
Fig. 6 Bilateral adrenal pheochromocytoma in a 27-year-old woman
with multiple endocrine neoplasia type 2. Axial T2-weighted fat-
saturated spin echo (a), three-dimensional fat-suppressed T1-
weighted gradient recalled echo images before contrast injection
(b), and in portal phase (c) images show a bilateral adrenal mass
with high T2 signal intensity and strong and heterogenous contrast
enhancement. The signal intensity is typically more inhomogenous
in larger lesions (white arrow, right adrenal gland) than in smaller
ones (black arrow, left adrenal gland)
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Lymphangiomas are rare adrenal incidentally discovered
benign lesions, being totally asymptomatic and occurring
at any age [57]. On CT, lymphangioma appears as a
well-encapsulated hypodense lesion (8–20 HU) with an
average size of 3 cm with intra-lesional septations show-
ing contrast enhancement. Lymphangioma can also con-
tain calcifications which appear scattered punctate or
thick curvilinear [58]. At MR, lymphangioma does not
display specific imaging features showing low signal in-
tensity on T1- and high signal on T2-weighted images.
Schwannoma
Schwannoma is a rare and usually benign tumor
arising from the sheath of the nerves, with only few
cases of adrenal schwannomas having been previ-
ously described [59]. This lesion is commonly
asymptomatic, but in some cases it may present with
abdominal pain, generally due to hemorrhage. At
CT, it appears as hypodense with inhomogeneous
contrast enhancement. Larger lesions usually present
degenerative changes including hemorrhagic compo-
nents, calcifications, and cystic areas, making MR
features non-specific, although adrenal schwannoma
generally appears isointense on T1-weighted images
showing slight hyperintensity on T2-weighted images
[59, 60].
Ganglioneuroma
Ganglioneuroma is a benign tumor arising from the
sympathetic nerves or within the adrenals. This lesion is
more frequently detected in the mediastinum or retro-
peritoneum than in the adrenal medulla [61]. Usually, it
is a small round mass (2–3 cm) with well-defined
smooth margins and an inhomogeneous appearance due
to mixoid components. On CT, it appears as a
well-circumscribed solid iso- or hypoattenuating lesion,
which may display calcifications, necrosis, and
hemorrhagic areas [62]. It remains hypoattenuating on
early post-contrastographic phases, while becoming
hyperattenuating on delayed phases due to persistent en-
hancement [62]. On MR, ganglioneuroma is hypointense
on T1-weighted and hyperintense on T2-weighted
Fig. 7 Right adrenal hemangioma in a 49-year-old woman. Coronal
reformatted CT images before (a) and after contrast injection in
arterial (b) and late phase (c) show a well-encapsulated large right
adrenal lesion (arrow) showing peripheral contrast enhancement
with progressive centripetal filling and a hypodense center
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post-contrastographic images [62].
Adenomatoid tumor
Adenomatoid tumor is an uncommon benign lesion
with mesothelial origin, which is generally asymptom-
atic. On CECT, this tumor appears as a hypoattenuat-
ing lesion with heterogeneous contrast enhancement.
Calcifications and septations may be observed within
the mass. MR findings are non-specific with a variable
appearance on T1-weighted, T2-weighted, and
post-contrast images [31].
Oncocytoma
Oncocytoma is a rare epithelial tumor affecting more
frequently the left adrenal and showing a mean size of
about 9 cm. This neoplasm is generally benign and
non-functioning, although few cases of functioning
lesions secreting cortisol and androgens have been previ-
ously reported [63]. According to the Lin-Weiss-
Bisceglia criteria, adrenal oncocytomas can be benign,
borderline malignant potential, and malignant lesions
[64]. Few malignant metastatic oncocytomas have been
described [65]. On CT and MR scans, the lesion appears
as a well-demarcated mass with heterogeneous contrast
enhancement due to degenerative changes [65]. Fibrous
encapsulation is a typical feature of oncocytoma, having
been observed in both benign and malignant variants
[65]. Unfortunately, the differentiation from cortical
carcinoma is still challenging, similar to that observed




Cortical carcinoma is an uncommon malignant ad-
renal tumor, with a bimodal peak of incidence in
childhood and middle age [66]. For unclear reasons,
it may be functioning especially in females, who also
show more frequently an association with endocrine
syndromes including Li-Fraumeni syndrome,
Beckwith-Wiedemann syndrome, Carney complex,
congenital adrenal hyperplasia, and MEN-1 [66, 67].
Non-functioning lesions are asymptomatic as long as
they become so large to determine compression and
dislocation of adjacent structures.
At US, this lesion presents as a large mass, generally
larger than 6 cm in size. Small lesions may show homo-
geneous echotexture, whereas larger lesions tend to be
more heterogeneous due to necrosis or hemorrhage
[13]. Intra-lesional echogenic foci due to calcifications
can be also observed. At Color Doppler, this lesion ap-
pears as a hypervascular mass, which may demonstrate
an afferent blood vessel [13]. CEUS reveals a
Fig. 8 Right cortical carcinoma in a 70-year-old woman admitted to
the emergency department for atraumatic abdominal pain. US (a)
shows a large heterogeneous right adrenal mass (arrow). Axial T2-
weighted spin echo (b), three-dimensional fat-suppressed T1-
weighted gradient recalled echo images before contrast injection
(c), in arterial phase (d) images confirm the presence of a large right
adrenal mass with necrotic and hemorrhagic components which
present as areas of high signal on unenhanced T1-weighted (c)
images and non-enhancing areas after contrast injection (d)
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to that of pheochromocytoma [14].
On CT, adrenal carcinoma shows a heterogeneous ap-
pearance due to necrosis, calcifications, and hemorrhage.
After intravenous contrast injection, it demonstrates het-
erogeneous and mainly peripheral enhancement [66]. As
previously reported, the RPW of the carcinoma tends to
be less than 40% [67]. Invasion of adjacent structures
such as kidney, inferior vena cava, and splenic vessels
are common as well as liver metastasis and retroperiton-
eal lymph nodal locations.
On MR, cortical carcinoma shows low signal inten-
sity on T1-weighted images, high signal on
T2-weighted images, and strong and heterogeneous
contrast enhancement with slow washout [68, 69].
Hemorrhagic areas may present as intra-lesional areas
of high signal intensity on T1-weighted images (Fig. 8)
[69]. Rarely, focal loss of signal intensity on
out-of-phase images due to foci of intracytoplasmic
fat may be observed [69].
Despite 18F-FDG-PET/CT not completely included
in the management algorithms of adrenal malignan-
cies, the potential value of this method has been pro-
posed as a second-line test in ruling out suspected
recurrences found by CT [70]. Furthermore, a recent
study by Cistaro et al. focused on the comparison of
18F-FDG-PET/CT with conventional imaging, showing
better accuracy of 18F-FDG-PET/CT (93.4%) in com-
parison to CECT (75%) [71]. Nevertheless, further
studies will be necessary to confirm these results and
its role in the clinical setting.
Lymphoma
The primary adrenal lymphoma is very rare, with the
secondary adrenal involvement being more frequent
[72]. In 50% of cases, a bilateral location is observed,
generally associated with retroperitoneal pathologic
lymph nodes [72]. On US, lymphoma appears as
hypoechoic with a homogenous or heterogeneous ap-
pearance [73]. On CT, primary adrenal lymphoma
appears as a single complex hypoattenuating mass,
without intra-lesional calcifications, showing slight
contrast enhancement (Fig. 9) [74]. In secondary
Fig. 9 Left adrenal lymphomatous lesion in a 70-year-old man with
non-Hodgkin lymphoma. Coronal reformatted CT images before (a)
and after contrast injection in portal phase (b) show a large left
adrenal mass (arrow) with inhomogeneous enhancement. Axial CT
image of the lower abdomen in portal phase (c; arrow) shows the
gastrointestinal involvement by lymphoma as aneurysmal dilatation
of some loops of the small bowel
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maintain normal morphology also being more homo-
geneous than primary lesions. On CECT, secondary
lymphomas show slight contrast enhancement and
slow washout [72]. At MR, adrenal lymphoma is
hypo/isointense on T1-weighted and slightly hyperin-
tense on T2-weighted images [72]. On DWI, lym-
phomatous lesions always show a restricted pattern
of diffusion due to their hypercellularity and high
nuclear-to-cytoplasmic ratio, leading to decreased
diffusivity of water molecules [75–78]. Nevertheless,
this imaging feature is not specific for adrenal
lymphoma, but detectable in all locations [79].
Metastases
Metastases are the most frequent malignant adrenal
lesions. The most common primary tumor metastasiz-
ing to the adrenal glands is lung cancer followed by
breast, colon, melanoma, kidney, and hepatocellular
carcinoma [80]. Bilateral metastases are more com-
mon than unilateral metastasis [80]. Metastases are
clinically silent, but in some cases extensive involve-
ment of both glands can determine adrenal insuffi-
ciency. CT is the method of choice in oncologic
patients, while US is used predominantly in pediatric
patients. MR is a second-instance method, useful only
for further characterization of adrenal lesions.
18F-FDG-PET/CT can be helpful to differentiate fat
poor adenoma from small metastasis [81].
At CT, adrenal metastases appear as focal masses with
strong and prolonged enhancement on the portal venous
phase, usually more than 120 HU, but slower washout
than adenomas (Fig. 10) [21]. At MR, imaging features
depend on the type of primary tumor, but generally ap-
pear hypointense on T1-weighted and moderately hyper-
intense on T2-weighted images. Metastases from
melanoma may show high signal intensity on
T1-weighted images. Moreover, adrenal metastases may
show hypointense areas on T2-weighted images with no
enhancement after contrast injection due to
hemorrhagic intra-lesional components (Fig. 11). An-
other important imaging feature, which may be helpful
to differentiate metastases from adenomas, is the lack of
signal loss on out-of-phase images [51]. Conversely, the
differential diagnosis between metastasis and primary
carcinoma is very difficult, as well as in other districts,
with carcinoma generally showing higher local invasive-
ness [82].
As a functional imaging modality, which provides
glucose metabolic information on malignant tumors,
18F-FDG-PET/CT has shown encouraging results for
the detection of adrenal metastases. Recently, a
meta-analysis of Wu et al. evaluating 707 lung cancer
patients with 810 adrenal masses has reported an
Fig. 10 Left adrenal metastasis in a 62-year-old woman with lung cancer. Unenhanced CT (a), portal (b), and late phase (c) images show a left
adrenal mass (arrow) with attenuation value of 26 HU on unenhanced CT (a) and “absolute percentage washout” of 15%. Staging 18F-FDG PET/CT
(d) performed 3 months later revealed a left adrenal lesion (arrow) with high metabolic activity (SUVmax 14 g/mL) and increased in size in
comparison with CT images. After chemotherapy, restaging 18F-FDG-PET/CT (e) showed morpho-functional disease progression of the adrenal
lesion (arrow) with signs of central necrosis (SUVmax 19 g/mL with central necrotic area of absence of
18F-FDG uptake). Images of 18F-FDG-PET/CT
provided by database of Nuclear Medicine Service, Fondazione Istituto G. Giglio, Cefalù, Italy
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supporting its clinical value in the differentiation of
adrenal metastases from benign masses [83]. A retro-
spective study conducted by Kim JY et al. on 325 pa-
tients evaluated a combination of morpho-functional
parameters using PET/CT demonstrating that unen-
hanced attenuation of > 10 HU at CT imaging and a
SUVmax ratio of > 2.5 in PET were significantly asso-
ciated with adrenal metastases [84]. Further, several
studies have compared CT with 8F-FDG-PET/CT in
this setting. The sensitivity of PET remains still lower
than CT due to a limited spatial resolution. For this
reason, given a superior specificity, 18F-FDG-PET/CT
could be considered as a second-stage imaging study
for evaluation of indeterminate adrenal lesions [85].
Neuroblastoma
Neuroblastoma is the second most common neoplasm
in childhood after Wilms tumor, being very rare in
adults [86]. This lesion usually presents calcification,
necrosis, and intra-lesional hemorrhage [86]. Gener-
ally, it is totally asymptomatic, becoming clinically
evident when it invades or compresses adjacent struc-
tures, metastasizes, or determines a paraneoplastic
clinical picture [87].
US is the first imaging modality for this lesion in
pediatric patients. Neuroblastoma appears as a large
lesion with inhomogeneous echotexture, intra-lesionalvascularity at color Doppler, and calcifications in
some cases [87]. On CT, it is a lobulated mass, with
amorphous or mottled calcifications, usually without
capsule and with mild contrast enhancement.
Intra-lesional calcifications are detected in 80–90% of
cases and represent an important finding to differenti-
ate this neoplasm from Wilms tumor [86, 87].
MR has shown to be more accurate than CT in the
characterization of these tumors. Neuroblastoma usually
shows a variable appearance, with low signal on
T1-weighted and high signal intensity on T2-weighted
images, demonstrating heterogeneous contrast enhance-
ment [86, 87].
The MIBG scintigraphy for the detection of this neo-
plasm has shown equal sensitivity to that for pheochro-
mocytoma [88].
Conclusion
The widespread use of imaging has dramatically in-
creased the detection of incidental adrenal lesions,
which are mostly benign and non-functioning aden-
omas. Nevertheless, differentiating a benign adrenal
lesion from a malignant one can be challenging and
is critical especially in oncology patients, since it will
greatly affect patient management. In this setting,
imaging plays a crucial role with several tools, which
can be employed in the attempt to characterize ad-
renal lesions. Radiologists should recall the strengths
Fig. 11 Left adrenal metastasis in a 58-year-old woman with breast cancer. Axial unenhanced CT (a), portal phase (b), T2-weighted fast spin echo
(c), b800 s/mm2 diffusion-weighted image (d), ADC map (e), and coronal three-dimensional fat-suppressed T1-weighted gradient recalled echo
image in portal phase after contrast injection (f) show a left adrenal mass (arrow). This lesion intra-lesional hemorrhage presenting as
spontaneously hyperdense area on unenhanced CT (a), hypointense on T2-weighted (c), and no enhancement on CT (b) and MR (f) images after
contrast injection. The peripheral solid component of the lesion shows also restricted pattern of diffusion (d, e)
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clinicians and surgeons in the management of pa-
tients, avoiding a misinterpretation of imaging fea-
tures which frequently overlap between benign and
malignant conditions.
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